Published in JAMA on September 12, 2012
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst (2013) 10.30
Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation (2017) 2.76
Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA (2012) 2.66
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol (2013) 2.60
Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol (2015) 2.11
Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet (2014) 1.75
Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician (2013) 1.67
Effects of oxidative stress on fatty acid- and one-carbon-metabolism in psychiatric and cardiovascular disease comorbidity. Acta Psychiatr Scand (2014) 1.65
Omega-3 fatty acids: mechanisms underlying 'protective effects' in atherosclerosis. Curr Opin Lipidol (2013) 1.46
Plasma phospholipid long-chain ω-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. Ann Intern Med (2013) 1.43
Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus. Rheumatol Int (2013) 1.41
A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents. J Pediatr (2014) 1.40
Diet and Stroke: Recent Evidence Supporting a Mediterranean-Style Diet and Food in the Primary Prevention of Stroke. Stroke (2015) 1.38
Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food Nutr Res (2014) 1.30
Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry (2013) 1.27
Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation (2015) 1.25
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis. J Am Heart Assoc (2013) 1.14
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol (2014) 1.14
Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity: A Comprehensive Review. Circulation (2016) 1.13
Marine omega-3 phospholipids: metabolism and biological activities. Int J Mol Sci (2012) 1.12
Individual variation in lipidomic profiles of healthy subjects in response to omega-3 Fatty acids. PLoS One (2013) 1.10
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol (2012) 1.10
Changes in fish consumption in midlife and the risk of coronary heart disease in men and women. Am J Epidemiol (2013) 1.08
ω-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies. JAMA Intern Med (2016) 1.05
A point mutation in the human Slo1 channel that impairs its sensitivity to omega-3 docosahexaenoic acid. J Gen Physiol (2013) 1.04
A flood of health functional foods: what is to be recommended? J Menopausal Med (2015) 1.03
Analysis of the omega-3 fatty acid content of South African fish oil supplements: a follow-up study. Cardiovasc J Afr (2013) 1.01
Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. JAMA Intern Med (2016) 1.01
Distinguishing health benefits of eicosapentaenoic and docosahexaenoic acids. Mar Drugs (2012) 0.99
Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol (2013) 0.99
Overview of omega-3 Fatty Acid therapies. P T (2013) 0.97
Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer. Prog Lipid Res (2013) 0.96
Greene et al. respond. Am J Public Health (2013) 0.95
Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report From the Workshop Convened by the World Heart Federation. J Am Coll Cardiol (2015) 0.95
Omega-3 index and cardiovascular health. Nutrients (2014) 0.94
Nutritional recommendations for cardiovascular disease prevention. Nutrients (2013) 0.94
Intake of long-chain ω-3 fatty acids from diet and supplements in relation to mortality. Am J Epidemiol (2014) 0.93
Omega-3 fatty acid supplementation and cardiovascular disease events. JAMA (2013) 0.93
Association of Specific Dietary Fats With Total and Cause-Specific Mortality. JAMA Intern Med (2016) 0.92
Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers. Mol Nutr Food Res (2013) 0.92
The 2015 Dutch food-based dietary guidelines. Eur J Clin Nutr (2016) 0.92
Fish intake and risks of total and cause-specific mortality in 2 population-based cohort studies of 134,296 men and women. Am J Epidemiol (2013) 0.91
Oxidation of marine omega-3 supplements and human health. Biomed Res Int (2013) 0.91
Omega-3 fatty acid supplementation and cardiovascular disease events. JAMA (2013) 0.91
Comment on: Satoh-Asahara et al. Highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia. Diabetes Care 2012;35:2631-2639. Diabetes Care (2013) 0.91
Omega-3 Polyunsaturated Fatty Acids: The Way Forward in Times of Mixed Evidence. Biomed Res Int (2015) 0.90
Omega-3 fatty acids for breast cancer prevention and survivorship. Breast Cancer Res (2015) 0.90
Association of dietary omega-3 fatty acids with prevalence of metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Clin Nutr (2013) 0.89
n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial. Vasc Med (2013) 0.89
Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med (2013) 0.88
Dietary polyunsaturated fatty acids and inflammation: the role of phospholipid biosynthesis. Int J Mol Sci (2013) 0.88
Omega-3 fatty acid supplementation and cardiovascular disease events. JAMA (2013) 0.88
Glycerol and fatty acids in serum predict the development of hyperglycemia and type 2 diabetes in Finnish men. Diabetes Care (2013) 0.88
Omega-3 fatty acid supplementation and cardiovascular disease events. JAMA (2013) 0.87
Saturated Fats Versus Polyunsaturated Fats Versus Carbohydrates for Cardiovascular Disease Prevention and Treatment. Annu Rev Nutr (2015) 0.87
Omega-3 Fatty Acids and Skeletal Muscle Health. Mar Drugs (2015) 0.86
Emerging nutrition science on fatty acids and cardiovascular disease: nutritionists' perspectives. Adv Nutr (2015) 0.85
ω-3 Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance. Int J Mol Sci (2015) 0.85
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care (2013) 0.85
Update on the Vitamin D and OmegA-3 trial (VITAL). J Steroid Biochem Mol Biol (2015) 0.85
21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo. J Int Soc Sports Nutr (2015) 0.85
Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial). J Am Heart Assoc (2015) 0.85
Omega-3 polyunsaturated fatty acids increase plasma adiponectin to leptin ratio in stable coronary artery disease. Cardiovasc Drugs Ther (2013) 0.85
2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation). Korean Circ J (2016) 0.84
Long-chain omega-3 polyunsaturated fatty acids and risk of stroke: a meta-analysis. Eur J Epidemiol (2012) 0.84
Associations of long-chain ω-3 fatty acids and fish intake with endometrial cancer risk in the VITamins And Lifestyle cohort. Am J Clin Nutr (2014) 0.84
Endogenously generated omega-3 fatty acids attenuate vascular inflammation and neointimal hyperplasia by interaction with free fatty acid receptor 4 in mice. J Am Heart Assoc (2015) 0.84
Role of fish oil in human health and possible mechanism to reduce the inflammation. Inflammopharmacology (2015) 0.83
The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis. BMC Cardiovasc Disord (2014) 0.83
Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach. J Intern Med (2014) 0.83
Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol (2013) 0.83
Dietary supplementation with Lovaza and krill oil shortens the life span of long-lived F1 mice. Age (Dordr) (2014) 0.83
Association of Plasma Phospholipid n-3 and n-6 Polyunsaturated Fatty Acids with Type 2 Diabetes: The EPIC-InterAct Case-Cohort Study. PLoS Med (2016) 0.83
The role of long-chained marine N-3 polyunsaturated Fatty acids in cardiovascular disease. Cardiol Res Pract (2012) 0.83
Mercury, selenium and fish oils in marine food webs and implications for human health. J Mar Biol Assoc U.K. (2015) 0.82
Press releases issued by supplements industry organisations and non-industry organisations in response to publication of clinical research findings: a case-control study. PLoS One (2014) 0.82
Complementary and alternative medicine and cardiovascular disease: an evidence-based review. Evid Based Complement Alternat Med (2013) 0.82
The association between dietary omega-3 fatty acids and cardiovascular death: the Singapore Chinese Health Study. Eur J Prev Cardiol (2013) 0.82
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry (2015) 0.82
Serum lipid profiles, the prevalence of dyslipidemia and the risk factors in two isolated Chinese minorities. Int J Clin Exp Med (2015) 0.82
Lifestyle Interventions Including Nutrition, Exercise, and Supplements for Nonalcoholic Fatty Liver Disease in Children. Dig Dis Sci (2016) 0.82
Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011. J Am Heart Assoc (2017) 0.82
Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®) REVEAL Trial. Mol Cell Biochem (2014) 0.81
Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis. BMC Pulm Med (2014) 0.81
Dietary α-Linolenic Acid, Marine ω-3 Fatty Acids, and Mortality in a Population With High Fish Consumption: Findings From the PREvención con DIeta MEDiterránea (PREDIMED) Study. J Am Heart Assoc (2016) 0.80
Effects of omega-3 polyunsaturated Fatty acids on heart function and oxidative stress biomarkers in pediatric patients with dilated cardiomyopathy. Int Cardiovasc Res J (2013) 0.80
Lifespan effects of simple and complex nutraceutical combinations fed isocalorically to mice. Age (Dordr) (2013) 0.80
Higher Plasma Phospholipid n-3 PUFAs, but Lower n-6 PUFAs, Are Associated with Lower Pulse Wave Velocity among Older Adults. J Nutr (2015) 0.80
High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2α concentrations relative to a control high-oleic acid meal: a randomized controlled trial. Am J Clin Nutr (2014) 0.80
Botanical oils enriched in n-6 and n-3 FADS2 products are equally effective in preventing atherosclerosis and fatty liver. J Lipid Res (2015) 0.80
Longitudinal and secular trends in dietary supplement use: Nurses' Health Study and Health Professionals Follow-Up Study, 1986-2006. J Acad Nutr Diet (2013) 0.80
Dietary supplements and risk of cause-specific death, cardiovascular disease, and cancer: a protocol for a systematic review and network meta-analysis of primary prevention trials. Syst Rev (2015) 0.80
Inflammatory bowel disease: can omega-3 fatty acids really help? Ann Gastroenterol (2016) 0.80
Fish oil and the pan-PPAR agonist tetradecylthioacetic acid affect the amino acid and carnitine metabolism in rats. PLoS One (2013) 0.79
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
'Racial' differences in genetic effects for complex diseases. Nat Genet (2004) 5.15
Genetic associations in large versus small studies: an empirical assessment. Lancet (2003) 3.41
Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet (2005) 2.21
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J (2004) 2.09
Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism (2006) 2.01
The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ (2002) 1.67
Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf (2008) 1.58
Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord (2012) 1.44
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. Perit Dial Int (2006) 1.42
Unexplained hypertransaminasaemia: clue to diagnosis of Addison's disease. Eur J Gastroenterol Hepatol (2002) 1.40
Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid (2003) 1.40
The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Curr Med Res Opin (2011) 1.39
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin (2006) 1.38
Establishment of genetic associations for complex diseases is independent of early study findings. Eur J Hum Genet (2004) 1.34
Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. Biol Psychiatry (2007) 1.32
Patellar resurfacing in total knee arthroplasty. A meta-analysis. J Bone Joint Surg Am (2005) 1.29
Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed (2008) 1.25
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs (2010) 1.18
An overview of the extra-lipid effects of rosuvastatin. J Cardiovasc Pharmacol Ther (2008) 1.16
The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol (2010) 1.14
Prevalence of vascular disease in metabolic syndrome using three proposed definitions. Int J Cardiol (2006) 1.12
Metformin and cancer. Eur J Pharmacol (2013) 1.11
Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care (2014) 1.08
Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Diabetologia (2015) 1.08
CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics (2005) 1.05
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality. Expert Opin Drug Saf (2008) 1.05
Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther (2005) 1.05
Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol (2010) 1.03
Vitamin D and metabolic syndrome: is there a link? Curr Pharm Des (2010) 1.02
Dyslipidemia in patients with thyroid disorders. Hormones (Athens) (2006) 1.01
Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies. Arthritis Rheumatol (2014) 1.00
Polymorphisms of the endothelin-1 gene associate with hypertension in patients with rheumatoid arthritis. Endothelium (2008) 0.99
Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke (2005) 0.99
Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail (2002) 0.97
Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome. Lipids (2008) 0.96
Correlation of Achilles tendon thickness evaluated by ultrasonography with carotid intima-media thickness in patients with familial hypercholesterolemia. Atherosclerosis (2006) 0.96
Risk factors for first-ever acute ischemic non-embolic stroke in elderly individuals. Int J Cardiol (2005) 0.95
Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol (2010) 0.94
Evaluation of alternative calculation methods for determining low-density lipoprotein cholesterol in hemodialysis patients. Clin Biochem (2004) 0.94
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology (2011) 0.94
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol (2013) 0.92
A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther (2007) 0.92
Statin pleiotropy against renal injury. J Cardiometab Syndr (2009) 0.92
The DOT1L rs12982744 polymorphism is associated with osteoarthritis of the hip with genome-wide statistical significance in males. Ann Rheum Dis (2013) 0.92
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate. J Cardiovasc Pharmacol Ther (2006) 0.91
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism (2012) 0.91
Severe hyperkalaemia in association with diabetic ketoacidosis in a patient presenting with severe generalized muscle weakness. Nephrol Dial Transplant (2003) 0.90
Effect of Plant Polyphenols on Adipokine Secretion from Human SGBS Adipocytes. Biochem Res Int (2011) 0.90
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin (2006) 0.89
The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol (2008) 0.89
Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes (2013) 0.89
Pathophysiology and management of fluid and electrolyte disturbances in patients on chronic dialysis with severe hyperglycemia. Semin Dial (2008) 0.89
Proton pump inhibitor-induced hypomagnesemia: A new challenge. World J Nephrol (2012) 0.88
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia. Expert Opin Pharmacother (2011) 0.88
Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci (2013) 0.88
Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol (2005) 0.87
Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol (2005) 0.87
The role of statins in chronic kidney disease. Am J Nephrol (2011) 0.87
Obstructive sleep apnea and cardiovascular risk: is metabolic syndrome the link? Angiology (2012) 0.87
Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother (2010) 0.86
Influence of apolipoprotein E polymorphisms on serum creatinine levels and predicted glomerular filtration rate in healthy subjects. Nephrol Dial Transplant (2004) 0.85
Pioglitazone and cancer: angel or demon? Curr Pharm Des (2013) 0.85
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol (2003) 0.85
Combination therapies of DPP4 inhibitors and GLP1 analogues with insulin in type 2 diabetic patients: a systematic review. Curr Vasc Pharmacol (2013) 0.85
Obstructive sleep apnoea syndrome and cardiovascular risk. Arch Med Sci (2012) 0.84
HPV infection, cervical abnormalities, and cancer in HIV-infected women in Mumbai, India: 12-month follow-up. Int J Womens Health (2013) 0.84
Hyponatremia in patients with heart failure. World J Cardiol (2013) 0.84
How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin (2014) 0.84
Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol (2011) 0.83
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vasc Health Risk Manag (2010) 0.83
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother (2011) 0.83
Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int (2004) 0.83
Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis (2013) 0.83
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol (2011) 0.83
The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment. Angiology (2011) 0.83
The impact of the metabolic syndrome on health-related quality of life: a cross-sectional study in Greece. Eur J Cardiovasc Nurs (2012) 0.83
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert Opin Drug Metab Toxicol (2014) 0.83
Fenofibrate and the kidney: an overview. Eur J Clin Invest (2013) 0.83
Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther (2009) 0.83
Different black box warning labeling for same-class drugs. J Gen Intern Med (2011) 0.82
Review article: effects of plant sterols and stanols beyond low-density lipoprotein cholesterol lowering. J Cardiovasc Pharmacol Ther (2010) 0.82
Simvastatin interactions with other drugs. Expert Opin Drug Saf (2012) 0.82
Emerging drugs for hyperlipidaemia: an update. Expert Opin Emerg Drugs (2014) 0.82
Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert Rev Cardiovasc Ther (2011) 0.82
Alcohol intake, serum uric acid concentrations, and risk of gout. Lancet (2004) 0.82
Exacerbation of tuberculosis enteritis after treatment with infliximab. Am J Med (2002) 0.82
A review of the lipid-related effects of fluvastatin. Curr Med Res Opin (2005) 0.82
Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough? Curr Vasc Pharmacol (2012) 0.82
Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol (2010) 0.82
Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol (2013) 0.82